X0306 4 2012-09-12 0 0001069308 Opexa Therapeutics, Inc. OPXA 0001476971 Thompson Jaye C/O OPEXA THERAPEUTICS, INC. 2635 TECHNOLOGY FOREST BLVD. THE WOODLANDS TX 77381 0 1 0 0 SVP Clinical Dev & Reg Affairs Employee Stock Option (right to buy) 3.80 2012-09-12 4 A 0 10469 0 A 2012-09-12 2022-01-06 Common Stock 10469 10469 D On January 6, 2012, the reporting person was granted an option to purchase an aggregate of 31,408 shares of common stock at the closing market price on such date. The option is performance based and begins to vest quarterly over a three-year period in two tranches commencing upon Opexa achieving certain key milestone events. The key milestone for vesting commencement of the first tranche of 10,469 shares is Opexa initiating a clinical trial for Tcelna in Secondary Progressive Multiple Sclerosis. The key milestone for vesting commencement of the second tranche of 20,939 shares is Opexa entering into a collaboration, partnership or other strategic arrangement involving rights in the United States for Tcelna. The performance criteria for the first key milestone has been met, resulting in commencement of three-year quarterly vesting for the first tranche of 10,469 shares reported herein. All share numbers and the exercise price have been adjusted to reflect the one-for-four reverse stock split implemented December 14, 2012. /s/ Jaye L. Thompson 2013-01-25